Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
China Car Sales Drop Again as EV Export Growth Surges in April 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
